Meiping Wang1, Fangyuan Xie1,2, Xikai Wen1, Han Chen3, Hai Zhang2, Junjie Liu1, He Zhang1, Hao Zou1, Yuan Yu1, Yan Chen1, Zhiguo Sun1, Xinxia Wang2, Guoqing Zhang2, Chuan Yin4, Duxin Sun5, Jie Gao1,5, Beige Jiang6, Yanqiang Zhong1, Ying Lu1. 1. Department of Pharmaceutical Sciences, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China. 2. Department of Pharmacy, Shanghai Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai 200438, China. 3. Department of General Surgery, 411 Hospital of Chinese People's Liberation Army, 15 East Jiangwan Road, Shanghai 200081, China. 4. Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China. 5. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA. 6. Third Department of HepaticSurgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Shanghai 200438, China.
Abstract
AIM: Salinomycin (SAL)-loaded PEG-ceramide nanomicelles (SCM) were prepared to target both liver cancer cells and cancer stem cells. MATERIALS & METHODS: The synergistic ratio of SAL/PEG-ceramide was evaluated to prepare SCM, and the antitumor activity of SCM was examined both in vitro and in vivo. RESULTS: SAL/PEG-ceramide molar ratio of 1:4 was chosen as the synergistic ratio, and SCM showed superior cytotoxic effect and increased apoptosis-inducing activity in both liver cancer cells and cancer stem cells. In vivo, SCM showed the best tumor inhibitory effect with a safety profile. CONCLUSION: Thus, PEG-ceramide nanomicelles could serve as an effective and safe therapeutic drug carrier to deliver SAL into liver cancer, opening up the avenue of using PEG-ceramide as therapeutic drug carriers.
AIM: Salinomycin (SAL)-loaded PEG-ceramide nanomicelles (SCM) were prepared to target both liver cancer cells and cancer stem cells. MATERIALS & METHODS: The synergistic ratio of SAL/PEG-ceramide was evaluated to prepare SCM, and the antitumor activity of SCM was examined both in vitro and in vivo. RESULTS:SAL/PEG-ceramide molar ratio of 1:4 was chosen as the synergistic ratio, and SCM showed superior cytotoxic effect and increased apoptosis-inducing activity in both liver cancer cells and cancer stem cells. In vivo, SCM showed the best tumor inhibitory effect with a safety profile. CONCLUSION: Thus, PEG-ceramide nanomicelles could serve as an effective and safe therapeutic drug carrier to deliver SAL into liver cancer, opening up the avenue of using PEG-ceramide as therapeutic drug carriers.
Entities:
Keywords:
cancer stem cells; ceramide; liver cancer; nanomicelles; salinomycin; therapeutic drug carriers
Authors: Sachin K Khiste; Zhijun Liu; Kartik R Roy; Mohammad B Uddin; Salman B Hosain; Xin Gu; Sami Nazzal; Ronald A Hill; Yong-Yu Liu Journal: Mol Cancer Ther Date: 2019-10-23 Impact factor: 6.261